Literature DB >> 32640555

Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance.

Jun Sik Yoon1,2, Dong Ho Lee3, Eun Ju Cho1, Mi Kyoung Song4, Young Hun Choi3, Gi Beom Kim4, Yun Bin Lee1, Jeong-Hoon Lee1, Su Jong Yu1, Haeryoung Kim5, Yoon Jun Kim1, Jung-Hwan Yoon1, Eun Jung Bae4.   

Abstract

Liver cirrhosis and hepatocellular carcinoma (HCC) are serious late complications that can occur after the Fontan procedure. This study aimed to investigate the cumulative incidence of cirrhosis and HCC and to identify specific features distinguishing HCC from benign arterial-phase hyperenhancing (APHE) nodules that developed after the Fontan operation. We retrospectively enrolled 313 post-Fontan patients who had been followed for more than 5 years and had undergone ultrasound or computed tomography (CT) of the liver between January 2000 and August 2018. Cirrhosis was diagnosed radiologically. The estimated cumulative incidence rates of cirrhosis at 5, 10, 20, and 30 years after the Fontan operation were 1.3%, 9.2%, 56.6%, and 97.9%, respectively. Multiphasic CT revealed that 18 patients had APHE nodules that were ≥1 cm in size and showed washout in the portal venous phase (PVP)/delayed phase, which met current noninvasive HCC diagnosis criteria. Among them, only seven patients (38.9%, 7/18) were diagnosed with HCC. After cirrhosis developed, the annual incidence of HCC was 1.04%. The appearance of washout in the PVP (p = 0.006), long time elapsed since the initial Fontan operation (p = 0.04), large nodule size (p = 0.03), and elevated serum α-fetoprotein (AFP) level (p < 0.001) were significantly associated with HCC. In conclusion, cirrhosis is a frequent late complication after Fontan operation, especially after 10 years, and HCC is not a rare complication after cirrhosis development. Diagnosis of HCC should not be based solely on the current imaging criteria, and washout on PVP and clinical features might be helpful to differentiate HCC nodules from benign APHE nodules.

Entities:  

Keywords:  Fontan-associated liver disease; hepatocellular carcinoma; liver cirrhosis; surveillance

Year:  2020        PMID: 32640555     DOI: 10.3390/cancers12071805

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Evaluation of Fontan-associated Liver Disease and Ethnic Disparities in Long-term Survivors of the Fontan Procedure: A Population-based Study.

Authors:  Juliet Emamaullee; Sean Martin; Cameron Goldbeck; Brittany Rocque; Arianna Barbetta; Rohit Kohli; Vaughn Starnes
Journal:  Ann Surg       Date:  2022-06-29       Impact factor: 13.787

2.  Shear wave dispersion to assess liver disease progression in Fontan-associated liver disease.

Authors:  Tomoaki Nagasawa; Hidekatsu Kuroda; Tamami Abe; Hirofumi Saiki; Yasuhiro Takikawa
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.

Authors:  Hiroyuki Suzuki; Takashi Niizeki; Tomotake Shirono; Yusuke Koteda; Yoshinao Kinjyo; Naohisa Mizukami; Makoto Koda; Satoshi Ota; Masahito Nakano; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Yu Noda; Naoki Kamachi; Akira Kajiwara; Kenji Suda; Jun Akiba; Hirohisa Yano; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

Review 4.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27

5.  The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.

Authors:  Xiaotian Shen; Beiyuan Hu; Jing Xu; Wei Qin; Yan Fu; Shun Wang; Qiongzhu Dong; Lunxiu Qin
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

6.  Pulmonary Arteriovenous Fistulae After Fontan Operation: Incidence, Clinical Characteristics, and Impact on All-Cause Mortality.

Authors:  Hideo Ohuchi; Aki Mori; Michikazu Nakai; Kazuto Fujimoto; Toru Iwasa; Heima Sakaguchi; Kenichi Kurosaki; Isao Shiraishi
Journal:  Front Pediatr       Date:  2022-06-09       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.